Impact BioMedical (IBO) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Impact BioMedical (IBO) has outperformed Nasus Pharma (NSRX) over the past year, losing 42.7% versus a loss of 47.6%. Nasus Pharma is the larger company by market cap ($42.5 million vs $35.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBO | NSRX |
|---|---|---|
| Share price | $4.11 | $3.63 |
| Market cap | $35.11M | $42.52M |
| 1-day change | -8.26% | -3.84% |
| YTD return | -29.92% | -58.74% |
| 1-year return | -42.73% | -47.64% |
| P/E ratio (TTM) | 0.37 | — |
| EPS (TTM) | $11.11 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.51 | $9.50 |
| 52-week low | $4.10 | $1.98 |
| Distance from 52-week high | -60.88% | -61.79% |
| Average volume | 11.61K | 16.09K |
| Shares outstanding | 8.54M | 11.71M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
IBO vs NSRX FAQ
Which is bigger, Impact BioMedical or Nasus Pharma?
Nasus Pharma (NSRX) is larger, with a market capitalization of $42.52M compared with $35.11M for Impact BioMedical (IBO).
Which stock has performed better over the past year, IBO or NSRX?
IBO returned -42.73% over the past 12 months, compared with -47.64% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are Impact BioMedical and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.